We performed an optimal dose-finding study of nartograstim, N-terminal amino acids-replaced rhG-CSF, for mobilization of PBPC in normal volunteers. Nartograstim was injected subcutaneously for 5 days (days 1-5) at a dose of 1 (n = 3), 2 (n = 3), 4 (n = 6) or 8 g/kg/day (n = 6), and blood samples were obtained by venipuncture on days 1 (pre-treatment), 4, 5 and 6. Nartograstim was well tolerated up to 8 g/kg/day. 
Nartograstim is the mutant growth factor by gene mutageneic techniques, in which amino acids were replaced at five positions of N-terminal region of intact recombinant human granulocyte colony-stimulating factor (rhG-CSF) as follows: Thr 1 , Leu 3 , Gly 4 , Pro 5 and Cys 17 of rhG-CSF to Ala 1 , Thr 3 , Tyr 4 , Arg 5 and Ser 17 . Previous reports have shown that nartograstim possesses superior biological activity [1] [2] [3] [4] [5] and stability 6, 7 compared with intact rhG-CSF. It has been recognized that allografting with PBSC can Correspondence: Dr T Nakahata, Department of Clinical Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan Received 6 January 1998; accepted 7 April 1998 be used as a realistic alternative to marrow stem cells for clinical transplantation because of avoiding general anesthesia in donors and the rapid recovery of leukocyte and platelet numbers in recipients. To mobilize PBPC more efficiently, rhG-CSF treatment has become one of the methods for the normal donor, [8] [9] [10] [11] and several groups have reported the results of primary transplantation using allogeneic PBPC mobilized by rhG-CSF. [12] [13] [14] [15] [16] On the other hand, it seems that there is a remarkable variability in the response to rhG-CSF in normal donors. 10, 11 Factors predicting the response to rhG-CSF in normal donors have been searched for. 17 The present phase I study was performed to confirm the safety and the effectiveness of nartograstim for PBPC mobilization in normal volunteers: we determined the kinetics of mobilization of various kinds of colony-forming cells, CD34 ϩ cells and their primitive subsets (CD33 Ϫ , 18 HLA-DR Ϫ , 19 CD38
Ϫ20
). We also determined the numbers of more primitive hematopoietic progenitors, long-term culture-initiating cells (LTC-IC), by limiting dilution analysis. The data show that nartograstim can mobilize not only clonogenic progenitors and CD34 ϩ cells but also LTC-IC in normal volunteers in a dose-related manner, and the optimal effect is obtained at 8 g/kg/day dose with acceptable side-effects.
Materials and methods

Eligibility of subjects
Normal healthy volunteers enrolled in this study fulfilled the following criteria: (1) male Japanese aged between 20 and 24 years; (2) weighted within the range of Ϯ20% of (stature Ϫ 100) ϫ 0.9; (3) excluded a past history of allergies to drugs, narcotism or alcoholism; (4) passed some virus checks; (5) negative to intradermal response to this trial drug; and (6) written, informed consent. This phase I study protocol was approved by the Institutional Review Board of the Kitasato Institute (Tokyo, Japan).
G-CSF administration
Nartograstim (genetical recombinant; Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) was administered subcutaneously for 5 consecutive days (on days 1-5) at the dose of 1 g/kg/day in three volunteers. Checking safety and effectiveness, dose escalation was performed as follows: 2 g/kg/day dose in three volunteers, 4 g/kg/day dose in six volunteers, finally, 8 g/kg/day dose in six volunteers. The dose of 8 g/kg/day was given divided into two injections to reduce subjective symptoms (ie 4 g/kg/once, twice/day, every 12 h). Clinical tests were performed on each day before administration, and when the peripheral WBC counts became more than 50 ϫ 10 6 /ml, dosing of nartograstim to the subject was reduced to 50% of the assigned dose.
To determine the number of PBPC, heparinized peripheral blood samples were taken pre-treatment and 3, 4, and 5 days after the first administration (ie on days 1, 4, 5 and 6).
Cytokines and antibodies
Recombinant human (rh) cytokines including IL-3, IL-6, SCF, GM-CSF and TPO were obtained from R&D Systems (Minneapolis, MN, USA). Recombinant human EPO was purchased from Boehringer Mannheim (Mannheim, Germany). All antibodies for flow cytometric analysis were purchased from Becton Dickinson Immunocytometry System (San Jose, CA, USA).
Clonogenic assays
Mononuclear cells (MNC) were separated from heparinized peripheral blood samples by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation after depletion of phagocytes with Silica (Immunological and Biochemical Laboratories, Fujioka, Japan). 21 The clonal assay for myeloid-erythroid progenitor cells was performed as previously reported. 11, [21] [22] [23] Briefly, 1 ml of culture mixture containing 1 ϫ 10 5 or 1 ϫ 10 4 MNC, ␣-MEM (ICN Biomedicals, Costa Mesa, CA, USA), 0.9% methylcellulose (Shinetsu Chemical, Tokyo, Japan), 30% FBS (Hyclone Laboratories, Logan, UT, USA), 1% deionized BSA (Sigma, St Louis, MO, USA), 5 ϫ 10 Ϫ5 mol/l 2-ME (Sigma), 10 ng/ml rhGM-CSF, 20 ng/ml rhIL-3, 80 ng/ml rhIL-6, 100 ng/ml rhSCF, 2 U/ml rhEPO was plated in a 35-mm Lux standard suspension culture dish (Nunc, Naperville, IL, USA), and incubated for 14 days at 37°C in a humidified atmosphere flushed with 5% CO 2 in air. All clonal cell cultures were performed in triplicate. Progenitor cell types were determined by observation of developed colonies on an inverted microscope in situ. Cell aggregates consisting of у50 cells were scored as colonies in the myeloid-erythroid system.
The clonal assay of megakaryocytic progenitor cells was performed as previously reported. 11, 21, 23, 24 The culture mixture was the same as described above with the exception that the growth factor combination was composed of 4 U/ml rhTPO, 20 ng/ml rhIL-3, 80 ng/ml rhIL-6, 100 ng/ml rhSCF, 2 U/ml rhEPO; 25% human platelet-poor plasma from healthy volunteers was used instead of FBS. Cultures were incubated for 13 days at 37°C in a humidified atmosphere flushed with a mixture of 5% CO 2 , 5% O 2 and 90% N 2 . All clonal cell cultures were performed in triplicate. Megakaryocytic colonies were determined by observation of developed colonies on an inverted microscope in situ. 11, [21] [22] [23] [24] [25] Megakaryocytes in the colonies were identified by their typical features of large cells that had nongranular, translucent cytoplasm and a highly refractile cell membrane. To assess the accuracy of the in situ identification of the megakaryocytes, individual colonies were lifted with an Eppendorf micropipette under direct microscopic visualization, spread on glass slides using a cytocentrifuge (Cytospin 2; Shandon Southern Instruments, Sewickley, PA, USA), and stained for morphological examination. Stainings with May-Grünwald-Giemsa and alkaline phosphatase antialkaline phosphatase method using a monoclonal antibody against human glycoprotein IIb/IIIa complex (Nichirei, Tokyo, Japan) were carried out as previously described. 21 Megakaryocyte colonies, defined as having four or more megakaryocytes were subdivided into two categories based on their proliferative capacity: colonies derived from megakaryocyte colony-forming unit (CFU-Meg) and megakaryocyte burst-forming unit (BFUMeg). 11 The CFU-Meg-derived colonies are defined as unicentric and having Ͻ100 megakaryocytes, whereas BFU-Meg-derived colonies have у100 megakaryocytes and are usually composed of two or more clusters that appear to burst from a common center. Morphologic examination of megakaryocyte-containing mixed colonies showed the coexistence of megakaryocytes and other lineage cells.
Abbreviations for progenitor cell types are as follows: CFU-GM, granulocyte-macrophage colony-forming unit; BFU-E, erythroid burst-forming unit; CFU-Mix, mixed colony-forming unit; CFU-Meg, megakaryocyte colony-forming unit; BFU-Meg, megakaryocyte burst-forming unit; Meg-Mix, megakaryocyte-containing mixed colony-forming unit; and Meg-CFC, total megakaryocytic colonyforming unit.
LTC-IC assay
This assay was performed by limiting dilution methods as previously described. [26] [27] [28] [29] [30] [31] For LTC medium, MyeloCult H5100 (Stem Cell Technologies, Vancouver, Canada) supplemented with 10 Ϫ6 mol/l hydrocortisone (Sigma), 100 U/ml penicillin and 100 g/ml streptomycin (GIBCO-BRL Life Technologies, Grand Island, NY, USA) was used. To prepare feeders, MNC isolated from bone marrow cells of normal healthy volunteers were used after informed consent. The MNC were cultured at a concentration of 2 ϫ 10 7 cells per T25 flask (Nunc) at 33°C in a humidified atmosphere flushed with 5% CO 2 in air. After culturing for 3 weeks, Ͼ80% of the confluent stromal layers were irradiated (1500 cGy of 250 kV peak X-rays) and trypsinized. The cells were resuspended in LTC medium and seeded in 96-well flat-bottomed microwell plates (Nunc) at 3 ϫ 10 4 cells per well for re-establishing the stromal feeder layer. The following day, the test cell suspensions of MNC were plated into each of the 96 wells at two-fold dilution. For limiting dilution analysis, eight wells were assigned for one concentration of the test cell suspension. The liquid cultures were incubated at 37°C in a humidified atmosphere flushed with 5% CO 2 in air, and fed weekly by replacement of half of the supernatant with fresh medium. After 5 weeks, the nonadherent and adherent cells were thoroughly collected from each well by pipetting, and plated in each methylcellulose culture medium with the same components as the myeloid-erythroid system described above. After incubation for 14 days at 37°C in a humidified atmosphere flushed with 5% CO 2 in air, the numbers of clonogenic cells (CFU-GM, BFU-E, CFU-Mix) in each culture dish were counted. The probability of LTC-IC in MNC was analyzed using Poisson statistics as previously described. 26, 27 We defined LTC-IC calculated for CFU-GM as LTC-IC GM , which could be sustained on stromal cells for at least 5 weeks in vitro with the latent ability to form myeloid colonies in the secondary culture. We also defined LTC-IC calculated for CFU-Mix as LTC-IC Mix , which could be sustained on stromal cells for at least 5 weeks in vitro with the latent ability to form mixed colonies in the secondary culture.
Flow cytometric analysis of CD34 ϩ cells and their subsets
The peripheral blood samples were also analyzed by double-color flow cytometry as previously described. 11 Briefly, cell preparations were obtained using NH 4 Cl lysis and the cell concentration was adjusted to 1 ϫ 10 6 cells/ml in PBS with 10% mouse serum. The cells were stained simultaneously with the FITC-conjugated CD34 Ab (HPCA-2) and one of the following phycoerythrin (PE)-conjugated monoclonal antibodies: CD33 Ab (Leu-M9), CD38 Ab (Leu-17), and HLA-DR Ab, for 30 min at 4°C in the dark. As isotype controls for the staining, we used FITC-conjugated mouse IgG1 and PE-conjugated mouse IgG1 or IgG2a. Flow cytometric analysis was performed with a FACScan (Becton Dickinson). The stained cells were selected for their small hypogranular morphology and the expression of CD34 antigen on two dimensional cytograms. Subsets of the CD34 ϩ cells were determined by the expression of CD33, HLA-DR or CD38 antigens. Each measurement included 1 ϫ 10 6 cells.
Statistical analysis
The baseline numbers were shown as mean Ϯ s. 
Results
Safety
Nartograstim injections were generally well tolerated, and in no case was treatment stopped. There was one case in which the WBC counts exceeded 50 ϫ 10 6 /ml on day 5 at 8 g/kg/day dose, so the last injected dose was reduced to 4 g/kg/day to the volunteer. Increasing dose was related to frequency and severity of side-effects, and every subject in the 8 g/kg/day dose group experienced some subjective or objective symptoms (Table 1) . Bone pains (lumbago and articular pain) could be controlled by the use of analgesics (acetaminophen or diclofenac sodium). All these symptoms resolved within a few days of nartograstim discontinuation. At 8 g/kg/day dose, two-to three-fold increases of serum lactate dehydrogenase and alkaline phosphatase were observed in all volunteers; a decrease of 35% in mean value of total choresterol level was seen; C-reactive protein was elevated to the positive level; the mean values of both GOT and GPT increased approximately 1.5-fold of basal levels; serum uric acid level increased at lesser extent; neutrophil counts decreased approximately 900 ϫ 10 3 /ml around day 12 in 50% (3/6) of the subjects; platelet counts decreased between days 9 and 12 in 50% (3/6) of the subjects, but the counts were not below 100 ϫ 10 6 /ml. All of these abnormalities were transient and returned to normal within a week of discontinuation. Parameters of the coagulation system measured as prothrombin time, activated partial thromboplastin time and serum fibrinogen concentration were not affected (data not shown). No antibody was detected against the replaced N-terminal amino acids of nartograstim (data not shown).
Effect of nartograstim dose on WBC count
The WBC counts increased up to day 6 at 4 and 8 g/kg/day doses of nartograstim, with a tendency to a Table 1 Adverse side-effects in normal volunteers receiving nartograstim administration Transient decreases of PLT were observed after discontinuation of nartograstim (between days 9 and 12), but the nadirs were not below 1 ϫ 10 8 /ml. LDH = serum lactate dehydrogenase; ALP = serum alkaline phosphatase; T-Cho = total choresterol; CRP = C-reactive protein; ANC = absolute neutrophil count; PLT = platelet count; UA = serum uric acid.
plateau from day 2 for the lower dose groups. The peak numbers at 1, 2, 4 and 8 g/kg/day doses were 14.6 (Ϯ1.2), 19.1 (Ϯ0.5), 34.5 (Ϯ6.9) and 46.7 (Ϯ5.3) ϫ 10 6 /ml, respectively, as mean (Ϯ s.d.). Most of the WBC subsets were neutrophils (data not shown). The number of monocytes also increased in a dose-related manner and reached approximately nine-fold above the baseline at 8 g/kg/day (data not shown). The number of lymphocytes increased approximately two-fold above the baseline in some volunteers with no relationship with the doses (data not shown). At 8 g/kg/day, WBC counts decreased below basal levels around day 12 in 83% (5/6) of the subjects, and recovered thereafter. Figure 1 illustrates the number of colony-forming cells in the blood obtained by venipuncture at 4 and 8 g/kg/day doses. The baseline numbers of CFU-GM, BFU-E, CFUMix and Meg-CFC were 120 Ϯ 76, 165 Ϯ 90, 25 Ϯ 13 and 0.6 Ϯ 1.7/ml, respectively, with no difference between the groups (one-way ANOVA, n = 18) in our experimental condition. After administration of nartograstim, all these progenitors were greatly mobilized with similar kinetics of a steady increase up to day 6. Median increases of each progenitor on day 6 at 1, 2, 4 and 8 g/kg/day doses were as follows: 12-, 11-, 40-and 120-fold increases of CFU-GM; five-, six-, 16-and 37-fold increases of BFU-E; six-, eight-, 20-and 50-fold increases of CFU-Mix above basal counts. While Meg-CFC were almost undetectable in the pre-treatment blood, the median counts on day 6 at these doses were 19, 62, 145 and 263/ml, respectively. These increases were dose-related at more than 2 g/kg/day. There was an individual heterogeneity in mobilization of Meg-CFC ( Figure  1d ) compared to myeloid and erythroid progenitor cells (Figures 1a, b and c) . Absolute numbers of Meg-CFC at 8 g/kg/day dose on days 1 (pre-treatment), 5 and 6 are presented in Table 2 . Notably, most of Meg-CFC were Meg-Mix (particularly, mixed erythroid-megakaryocyte Results are expressed as the median and the ranges per ml of the peripheral blood.
Kinetics and characteristics of colony-forming cells
colony-forming units, data not shown) rather than the unilineage progenitors (ie CFU-Meg and BFU-Meg).
Effect on LTC-IC mobilization
Peripheral LTC-IC counts were analyzed on days 1 and 6. Besides the number of LTC-IC for CFU-GM (LTC-IC GM ), that for CFU-Mix (LTC-IC Mix ) could be determined by limiting dilution technique in this study. Counts of both LTC-IC GM and LTC-IC Mix in the blood increased in all volunteers after administration of nartograstim (Table 3) , and these increases seemed to be directly proportional to the doses. The dose dependency was statistically significant for LTC-IC Mix counts from 2 to 8 g/kg dose levels (by Jonckheere, P = 0.0091). At 8 g/kg/day dose, LTC-IC GM counts increased approximately 100-to 1000-fold above initial counts; LTC-IC Mix , which were almost undetectable in pre-treatment, could also be obtained with a median number of 15.7/ml.
Kinetics and characteristics of CD34 ϩ cells
We analyzed the mobilized cells expressing the CD34 antigen and illustrated their counts of 4 and 8 g/kg/day dose levels (Figure 2 ). The baseline number of CD34 ϩ cells in the blood was 1.3 (Ϯ0.5) ϫ 10 3 /ml with no difference between the groups (one-way ANOVA, n = 18). After administration of nartograstim, CD34 ϩ cells were greatly mobilized with a maximal response on day 5 or 6 in all volunteers (Figure 2a) . Median increases on a peak day for each volunteer at 1, 2, 4 and 8 g/kg/day doses were six-, four-, 16-and 52-fold above basal counts. The difference between 1 and 2 g/kg/day doses was not statistically significant, and there was a dose-related increase at more than 2 g/kg/day. The median cloning efficiency of peripheral CD34 ϩ cells, as determined by dividing the number of total colony-forming cells by the number of CD34 ϩ cells, was Table 3 The numbers of LTC-IC for CFU-GM and CFU-Mix per ml of the peripheral blood in normal volunteers before and after nartograstim administration at different dose levels slightly changed at 8 g/kg/day dose: 26% (range, 20-49%) on day 1, 18% (range, 14-23%) on day 5, and 43% (range, 32-53%) on day 6 (n = 6, Figures 1 and 2a) . Although the difference between days 5 and 6 was statistically significant (two-way ANOVA, P = 0.0002; paired ttest comparing day 5 with day 6, P Ͻ 0.001), both of these cloning efficiencies were not statistically different from that of day 1. For the presumably immature subpopulation of CD34 ϩ cells, we analyzed CD33 Ϫ , HLA-DR Ϫ and CD38 Ϫ fractions. The baseline numbers of CD34 ϩ CD33 Ϫ , CD34
ϩ HLA-DR Ϫ and CD34 ϩ CD38 Ϫ cells were 63 Ϯ 64, 27 Ϯ 21 and 13 Ϯ 11/ml, respectively, with no difference between the groups (one-way ANOVA, n = 18). As shown in Figure 2b , CD34 ϩ CD33 Ϫ cells were significantly mobilized around days 5 and 6. CD34
ϩ HLA-DR Ϫ cells were also greatly mobilized with a median peak on day 5 (Figure 2c ). There was a dose-related increase in median peak number of these immature subtypes at more than 2 g/kg/day (data not shown). Additionally, peripheral CD34 ϩ CD38 Ϫ cells also increased at 8 g/kg/day dose with a median peak of 147/ml on day 5 (Figure 2d ). This increase was statistically significant and occurred in all volunteers (two-way ANOVA, P = 0.045 for days, P = 0.23 for volunteers, n = 6). However, there was a considerable individual heterogeneity of mobilization in terms of the number and the peak day.
Correlation between CD34
ϩ cell and progenitor cell counts after mobilization
The number of CD34 ϩ cells correlated well with that of colony-forming cells, measured as CFU-GM (R s = 0.954), BFU-E (R s = 0.929), CFU-Mix (R s = 0.924) and Meg-CFC (R s = 0.829), after being plotted with 54 cases from the total 18 donors for the 3 days of mobilization (ie, on days 4-6, data not shown). Additionally, the number of CD34 ϩ cells also correlated, though less well, with that of LTC- IC on day 6, measured either as LTC-IC GM (R s = 0.720, n = 9) or as LTC-IC Mix (R s = 0.718, n = 15) (data not shown). These results show that the number of CD34 ϩ cells is a useful parameter to estimate both the colony-forming cells and the LTC-IC in the blood.
Prediction of mobilization
Finally, we attempted to predict each volunteer's capability of PBPC mobilization by means of the number of CD34 
Discussion
In this study, we analyzed the quality of PBPC mobilized by nartograstim, N-terminal amino acids-replaced rhG-CSF, in normal volunteers. Nartograstim mobilized many types and numbers of PBPC, and this effect was doserelated. Increases of the dose between 2 and 8 g/kg/day were associated with a trend towards better mobilization. The median peak numbers of each PBPC at 8 gkg/day dose were as follows: CD34 ϩ cell, 82.8 ϫ 10 3 /ml; CFU-GM, 16.7 ϫ 10 3 /ml; BFU-E, 5.8 ϫ 10 3 /ml; CFU-Mix, 1.9 ϫ 10 3 /ml; Meg-CFC, 263/ml; and LTC-IC GM , more than 90/ml. The mean peak number of WBC was 46.7 ϫ 10 6 /ml in this condition. We compared these results with those of filgrastim (intact rhG-CSF) [9] [10] [11] and lenograstim (glycosylated rhG-CSF), 32 and found that nartograstim could give a comparable mobilization of PBPC.
It remains unclear whether PBPC mobilized with rhG-CSF have an adequate capacity to sustain long-term hematopoiesis. In addition to the general LTC-IC for CFU-GM (LTC-IC GM ), we successfully determined the number of LTC-IC for CFU-Mix (LTC-IC Mix ) by limiting dilution technique. LTC-IC Mix can be sustained on allogeneic stromal cells for at least 5 weeks in vitro with the latent multipotential ability to form mixed colonies in the secondary culture, while LTC-IC GM forms only myeloid colonies in the secondary culture. LTC-IC Mix were almost undetectable in the peripheral blood of normal volunteers in pre-treatment, but they appeared in all subjects in a dose-dependent manner on nartograstim. Primitive immunophenotypes (CD33 Ϫ , HLA-DR Ϫ , CD38 Ϫ ) of CD34 ϩ cells were also mobilized in a dose-related manner in this study. Particularly, CD38 was reported as the lineage-committed antigen of human CD34 ϩ cells. 20 It was also reported that the CD34 ϩ CD38 Ϫ cells contained more LTC-IC that could be sustained on stromal cells for longer periods. 33 Therefore, we thought that PBPC mobilized with nartograstim should contain the immature populations that contribute to longterm hematopoiesis.
The mobilization of colony-forming cells did not parallel that of CD34 ϩ cells and their primitive immunophenotypes at the 8 g/kg/day dose: the peak of colony-forming cells was on day 6, while that of CD34 ϩ cells was on day 5. We considered that CD34 ϩ cells mobilized on day 6 might be richer in colony-forming cells than those on day 5.
There seems to be a remarkable variability in the response to rhG-CSF in normal donors. 10, 11 Although a similar variability in response was observed in normal donors receiving nartograstim, there was a clear doserelated effect beyond the variability in this study. The correlation between the donor's characteristics and CD34 ϩ cell yield after treatment of rhG-CSF was reported with a view to predicting the donor's individual response, in which the donor's age was the significant factor while its predictive value was low. 17 It was also reported that the peripheral CD34 ϩ cell counts and colony-forming cell counts in steady state allowed estimation of the yield of mobilized CD34 ϩ cells after rhG-CSF-supported cytotoxic chemotherapy in auto-PBSCT. 34 We propose here that the peripheral CD34 ϩ cell counts in steady state may also be a useful parameter to predict each healthy volunteer's capability for mobilization of PBPC after administration of nartograstim in allo-PBSCT. The person with many CD34 ϩ cells per milliliter of peripheral blood in steady state may be a good donor for mobilization of CD34 ϩ cells and CD34 ϩ CD38 Ϫ cells (CD34 ϩ cell counts reflected both the colony-forming cell counts and LTC-IC counts in this study).
Nartograstim up to the 8 g/kg/day dose was well tolerated overall. Similar to the previous reports of rhG-CSF, 35 the main adverse effect was bone pain, but it could be managed with minor analgesics. On the other hand, some volunteers experienced a transient and slight decrease in platelet counts and/or a transient WHO grade 3 decrease in neutrophil counts after discontinuation of nartograstim. The transient neutropenia was also reported in normal donors after mobilization with filgrastim and PBPC apheresis. 36 Our results indicate that these transient decreases may occur only with the consecutive administration of relatively high doses of G-CSF in some normal donors without leukapheresis. Some attention should be paid not only to platelets but also to neutrophils for recovery of donors in allogeneic setting, especially for donors with relatively low basal counts. Because the transient neutropenia was observed after a great increase of neutrophil counts and nartograstim discontinuation, we thought that it was caused by the 'sponge effect' of mature neutrophils as a result of the increased clearance of G-CSF by their G-CSF receptors and/or by the down-regulation of endogenous production of G-CSF. The reason for the transient reduction of the platelet counts is unclear. It might be caused by the preferential hematopoiesis of myeloid progenitors in bone marrow or by some activation of platelets through their G-CSF receptors. The three coagulation tests (prothrombin time, activated partial thromboplastin time and serum fibrinogen concentration), however, were not affected in this study.
Based on these data, we conclude that the optimal dose of nartograstim for the mobilization of PBPC in allo-PBSCT setting is 8 g/kg/day for 5 consecutive days. Further studies are necessary to determine whether rapid and sustained engraftment will be obtained in the allogeneic setting and to confirm the donor's health for a long period.
